Ascentage Pharma Group International (AAPG) Total Non-Current Liabilities: 2023-2024

  • Ascentage Pharma Group International's Total Non-Current Liabilities fell 22.37% to $161.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $161.3 million, marking a year-over-year decrease of 22.37%. This contributed to the annual value of $161.3 million for FY2024, which is 23.80% down from last year.
  • As of Q4 2024, Ascentage Pharma Group International's Total Non-Current Liabilities stood at $161.3 million, which was down 22.37% from $207.7 million recorded in Q4 2023.
  • Ascentage Pharma Group International's Total Non-Current Liabilities' 5-year high stood at $207.7 million during Q4 2023, with a 5-year trough of $161.3 million in Q4 2024.
  • Moreover, its 2-year median value for Total Non-Current Liabilities was $184.5 million (2023), whereas its average is $184.5 million.
  • Data for Ascentage Pharma Group International's Total Non-Current Liabilities shows a maximum YoY decreased of 22.37% (in 2024) over the last 5 years.
  • Over the past 2 years, Ascentage Pharma Group International's Total Non-Current Liabilities (Quarterly) stood at $207.7 million in 2023, then dropped by 22.37% to $161.3 million in 2024.